Dr Ibrahim Aldoss speaks to ecancer about his talk at the ALL Assembly 2021. He discusses the optimal use of asparaginase for ALL and initially gives a brief history of the drug and its role in cancer treatment.
He then discusses the use of aspariginase for ALL treatment. Dr Aldoss talks about the toxicity profile and the age limit for asparignase use in treating ALL. He also mentions the optimal doses of this drug for children and adults.
Dr Aldoss lists some toxicity related complications for asparaginase such as pancreatitis, thrombosis and hypersensitivity to this drug. He concludes by discussing when to switch drugs for treating ALL.